New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study

Basit Öğe Kaydı
dc.authoridOzcan, Kazim Serhan/0000-0002-5321-442X
dc.authoridAskin, Lutfu/0000-0001-7768-2562
dc.authoridCanpolat, Ugur/0000-0002-4250-1706
dc.authoridözpamuk karadeniz, fatma/0000-0001-5839-9104
dc.authoridGulel, Okan/0000-0002-7932-6227
dc.authoridGülel, Okan/0000-0002-7932-6227
dc.authoridSinan, Umit/0000-0002-4837-7099
dc.authorwosidGulel, Okan/JCO-1582-2023
dc.authorwosidOzden, Ozge/GOH-2990-2022
dc.authorwosidOzcan, Kazim Serhan/O-3365-2018
dc.authorwosidAskin, Lutfu/H-1047-2018
dc.authorwosidPEHLIVANOGLU, SECKIN/ABC-9264-2021
dc.authorwosidCanpolat, Ugur/S-3482-2018
dc.authorwosidÜnlü, Serkan/AAA-3477-2020
dc.contributor.authorAltay, Servet
dc.contributor.authorYildirimturk, Ozlem
dc.contributor.authorCakmak, Huseyin Altug
dc.contributor.authorAskin, Lutfu
dc.contributor.authorSinan, Umit Yasar
dc.contributor.authorBesli, Feyzullah
dc.contributor.authorGedikli, Omer
dc.date.accessioned2024-06-12T11:09:12Z
dc.date.available2024-06-12T11:09:12Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). In this study, we aimed to evaluate the current patterns of NOACs treatment in Turkey. Moreover, demographic and clinical parameters and bleeding and/or embolic events under NOACs treatment were analyzed. Methods: The New Oral Anticoagulants-TURKey (NOAC-TURK) study was designed as a multicenter cross-sectional study. A total of 2,862 patients from 21 different centers of Turkey under the treatment of NOACs for at least three months were included in this study. Demographic, clinical, and laboratory characteristics of study participants with their medications used were obtained through the NOAC-TURK survey database. Additional necessary medical records were obtained from electronic health records of participating centers. Results: Of the 2. 862 patients, 1.131 (39.5%) were male and the mean age was 70.3 +/- 10.2 years. Hypertension was found as the most frequent comorbidity (81%). The most common indication for NOACs was permanent atrial fibrillation (83.3%). NOACs were mainly preferred because of inadequate therapeutic range or overdose during warfarin usage. The most frequent complication was bleeding (n=217, 7.6%), and major bleeding was observed in 1.1% of the patients. Embolic events were observed in 37 patients (1.3%). Rivaroxaban and dabigatran were both more preferred than apixaban. Almost half of the patients (47.6%) were using lower doses of NOACs, which is definitely much more than expected. Conclusion: The NOAC-TURK study showed an important overview of the current NOACs treatment regimens in Turkey. Although embolic and bleeding complications were lower than or similar to previous studies, increased utilization of low-dose NOACs in this study should be considered carefully. According to the results of this study, NOACs treatment should be guided through CHA(2)DS(2)-VASc and HASBLED scores to ensure more benefit and less adverse effects in NVAF patients.en_US
dc.description.sponsorshipTurkish Society of Cardiologyen_US
dc.description.sponsorshipThe study was funded by Turkish Society of Cardiology.en_US
dc.identifier.doi10.14744/AnatolJCardiol.2016.7472
dc.identifier.endpage361en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue5en_US
dc.identifier.pmid28100898en_US
dc.identifier.scopus2-s2.0-85018902719en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage353en_US
dc.identifier.trdizinid227537en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2016.7472
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/227537
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22712
dc.identifier.volume17en_US
dc.identifier.wosWOS:000403533300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Soc Cardiologyen_US
dc.relation.ispartofAnatolian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNew Oral Anticoagulantsen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectEmbolic Complicationen_US
dc.subjectBleedingen_US
dc.subjectAtrial-Fibrillationen_US
dc.subjectStroke Incidenceen_US
dc.subjectCase-Fatalityen_US
dc.subjectRisk-Factorsen_US
dc.subjectMortalityen_US
dc.subjectWarfarinen_US
dc.subjectThromboembolismen_US
dc.subjectTrendsen_US
dc.titleNew oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu